3,4-dihydroxyphenylacetic acid has been researched along with Atherosclerotic Parkinsonism in 112 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 5.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| " N-Methyl(R)salsolinol induced DNA damage to human neuroblastoma SH-SY5Y cells, which could be prevented by anti-oxidants and cycloheximide." | 3.70 | Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. ( Dostert, P; Kasamatsu, T; Maruyama, W; Naoi, M, 1998) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "Hesperidin is a flavonoid glycoside that is frequently found in citrus fruits." | 1.62 | Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis. ( Antunes, MS; Boeira, SP; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL, 2021) |
| "Oral treatment with chrysin (10 mg/kg, 28 days), culminated with the prevention of these alterations occasioned by 6-OHDA." | 1.48 | Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. ( Antunes, MS; Boeira, SP; Goes, ATR; Jesse, CR; Lobo Ladd, AAB; Lobo Ladd, FV; Luchese, C; Paroul, N, 2018) |
| "Reactive gliosis occurred only in response to combined PQ + MB in dorsal-medial but not ventral striatum." | 1.31 | The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. ( Baggs, RB; Cory-Slechta, DA; Richfield, EK; Tank, AW; Thiruchelvam, M, 2000) |
| " A similar dose-response relationship was determined for nifedipine, an L-type calcium channel antagonist." | 1.31 | Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. ( Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH, 2001) |
| " We show in this study that repin is highly toxic to C57BL/6J mice and Sprague-Dawley rats and acutely induces uncoordinated locomotion associated with postural tremors, hypothermia, and inability to respond to sonic and tactile stimuli." | 1.30 | Repin-induced neurotoxicity in rodents. ( Choi, BH; Han, B; Kim, RC; Robles, M; Santa Cruz, K, 1998) |
| "Levodopa treatment in Parkinson's disease has been suggested to contribute to disease progression through free radical generation." | 1.30 | Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation. ( Arnold, LA; Camp, DM; Hyland, K; Juneau, PL; LeWitt, PA; Loeffler, DA, 1998) |
| "Pretreatment with riluzole (8 mg kg-1, i." | 1.29 | Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. ( Boireau, A; Doble, A; Dubédat, P; Meunier, M; Miquet, JM, 1994) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| " Chronic administration of L-deprenyl (0." | 1.28 | Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. ( Hashim, A; Lajtha, A; Sershen, H; Wiener, HL, 1989) |
| "In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine." | 1.27 | Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (23.21) | 18.7374 |
| 1990's | 46 (41.07) | 18.2507 |
| 2000's | 29 (25.89) | 29.6817 |
| 2010's | 9 (8.04) | 24.3611 |
| 2020's | 2 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Antunes, MS | 2 |
| Ladd, FVL | 1 |
| Ladd, AABL | 1 |
| Moreira, AL | 1 |
| Boeira, SP | 3 |
| Cattelan Souza, L | 2 |
| Sun, J | 1 |
| He, C | 1 |
| Yan, QX | 1 |
| Wang, HD | 1 |
| Li, KX | 1 |
| Sun, X | 1 |
| Feng, Y | 1 |
| Zha, RR | 1 |
| Cui, CP | 1 |
| Xiong, X | 1 |
| Gao, S | 1 |
| Wang, X | 1 |
| Yin, RX | 1 |
| Qiao, GF | 1 |
| Li, BY | 1 |
| Madiha, S | 1 |
| Tabassum, S | 1 |
| Batool, Z | 1 |
| Liaquat, L | 1 |
| Sadir, S | 1 |
| Shahzad, S | 1 |
| Perveen, T | 1 |
| Haider, S | 1 |
| Goes, ATR | 1 |
| Jesse, CR | 2 |
| Lobo Ladd, FV | 2 |
| Lobo Ladd, AAB | 2 |
| Luchese, C | 1 |
| Paroul, N | 1 |
| Del Fabbro, L | 1 |
| Rossito Goes, A | 1 |
| de Gomes, MG | 1 |
| Nunes Arantes, RV | 1 |
| Reis Simionato, A | 1 |
| Oliveira, MS | 1 |
| Furian, AF | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| Yu, LH | 1 |
| Wei, HL | 1 |
| Bao, XQ | 1 |
| Zhang, D | 1 |
| Sun, H | 1 |
| Goldstein, DS | 1 |
| Sullivan, P | 1 |
| Cooney, A | 1 |
| Jinsmaa, Y | 1 |
| Kopin, IJ | 1 |
| Sharabi, Y | 1 |
| Moraes, LS | 1 |
| Rohor, BZ | 1 |
| Areal, LB | 1 |
| Pereira, EV | 1 |
| Santos, AM | 1 |
| Facundo, VA | 1 |
| Santos, AR | 1 |
| Pires, RG | 1 |
| Martins-Silva, C | 1 |
| Joniec, I | 1 |
| Ciesielska, A | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Przybylkowski, A | 1 |
| Czlonkowska, A | 1 |
| Czlonkowski, A | 1 |
| Thakur, P | 1 |
| Nehru, B | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 2 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 2 |
| Cory-Slechta, DA | 2 |
| Di Monte, DA | 2 |
| Choi, JY | 1 |
| Park, CS | 1 |
| Kim, DJ | 1 |
| Cho, MH | 1 |
| Jin, BK | 1 |
| Pie, JE | 1 |
| Chung, WG | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 3 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 2 |
| Cohen, AD | 2 |
| Tillerson, JL | 2 |
| Smith, AD | 1 |
| Schallert, T | 3 |
| Zigmond, MJ | 2 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, XF | 1 |
| Gu, SD | 1 |
| Zhuo, M | 1 |
| Xu, DH | 1 |
| Cao, L | 1 |
| Xu, LF | 1 |
| Yu, FR | 1 |
| Zheng, ZC | 1 |
| Liu, XY | 1 |
| Ahmad, AS | 1 |
| Ansari, MA | 1 |
| Ahmad, M | 1 |
| Saleem, S | 1 |
| Yousuf, S | 1 |
| Hoda, MN | 1 |
| Islam, F | 1 |
| Taylor, JL | 1 |
| Bishop, C | 1 |
| Walker, PD | 1 |
| Li, X | 1 |
| Matsumoto, K | 1 |
| Murakami, Y | 1 |
| Tezuka, Y | 1 |
| Wu, Y | 1 |
| Kadota, S | 1 |
| Chaturvedi, RK | 1 |
| Shukla, S | 1 |
| Seth, K | 1 |
| Agrawal, AK | 1 |
| Cannon, JR | 1 |
| Keep, RF | 1 |
| Hua, Y | 1 |
| Richardson, RJ | 1 |
| Xi, G | 2 |
| Rojo, AI | 1 |
| Cavada, C | 1 |
| de Sagarra, MR | 1 |
| Cuadrado, A | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Jenner, P | 4 |
| Rupniak, NM | 1 |
| Rose, S | 4 |
| Kelly, E | 2 |
| Kilpatrick, G | 2 |
| Lees, A | 1 |
| Marsden, CD | 5 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Huston, JP | 1 |
| Wesemann, W | 2 |
| Grote, C | 2 |
| Clement, HW | 2 |
| Block, F | 1 |
| Sontag, KH | 2 |
| Boireau, A | 3 |
| Dubédat, P | 2 |
| Bordier, F | 1 |
| Peny, C | 1 |
| Miquet, JM | 2 |
| Durand, G | 1 |
| Meunier, M | 2 |
| Doble, A | 2 |
| Nomoto, M | 3 |
| Irifune, M | 1 |
| Fukuzaki, K | 1 |
| Fukuda, T | 1 |
| Sarre, S | 1 |
| De Klippel, N | 1 |
| Herregodts, P | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Pérez-Otaño, I | 1 |
| Oset, C | 1 |
| Luquin, MR | 1 |
| Herrero, MT | 1 |
| Obeso, JA | 1 |
| Del Río, J | 1 |
| Albanese, A | 2 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Schneider, JS | 5 |
| DiStefano, L | 3 |
| Gomez-Mancilla, B | 1 |
| Boucher, R | 3 |
| Gagnon, C | 1 |
| Di Paolo, T | 4 |
| Markstein, R | 1 |
| Bédard, PJ | 3 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Solbach, M | 1 |
| Nafe, R | 1 |
| Riederer, P | 3 |
| Jellinger, K | 2 |
| Mennel, HD | 1 |
| Cintra, A | 1 |
| Andbjer, B | 1 |
| Finnman, UB | 1 |
| Hagman, M | 1 |
| Agnati, LF | 1 |
| Höglund, G | 1 |
| Fuxe, K | 1 |
| Royland, JE | 1 |
| Jakowec, MW | 1 |
| Hattori, S | 1 |
| Hashitani, T | 2 |
| Matsui, N | 1 |
| Nishino, H | 2 |
| Gerlach, M | 1 |
| Gsell, W | 1 |
| Kornhuber, J | 1 |
| Krieger, V | 1 |
| Pantucek, F | 1 |
| Vock, R | 1 |
| Sullivan, AM | 1 |
| Opacka-Juffry, J | 1 |
| Hötten, G | 1 |
| Pohl, J | 1 |
| Blunt, SB | 1 |
| Zhu, W | 1 |
| Ju, J | 1 |
| Matsubara, K | 1 |
| Gonda, T | 1 |
| Sawada, H | 1 |
| Uezono, T | 1 |
| Kobayashi, Y | 1 |
| Kawamura, T | 1 |
| Ohtaki, K | 1 |
| Kimura, K | 1 |
| Akaike, A | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Kasamatsu, T | 1 |
| Dostert, P | 1 |
| Mizukawa, K | 1 |
| Kumazaki, M | 1 |
| Horger, BA | 1 |
| Nishimura, MC | 1 |
| Armanini, MP | 1 |
| Wang, LC | 1 |
| Poulsen, KT | 1 |
| Rosenblad, C | 1 |
| Kirik, D | 1 |
| Moffat, B | 1 |
| Simmons, L | 1 |
| Johnson, E | 1 |
| Milbrandt, J | 1 |
| Rosenthal, A | 1 |
| Bjorklund, A | 1 |
| Vandlen, RA | 1 |
| Hynes, MA | 1 |
| Phillips, HS | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Di Rocco, A | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Yahr, MD | 1 |
| Robles, M | 1 |
| Choi, BH | 1 |
| Han, B | 1 |
| Santa Cruz, K | 1 |
| Kim, RC | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Hyland, K | 2 |
| Arnold, LA | 2 |
| Pettigrew, KD | 1 |
| Chase, TN | 1 |
| Loeffler, DA | 1 |
| LeWitt, PA | 1 |
| Juneau, PL | 1 |
| Camp, DM | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Kucherianu, VG | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Kudrin, VS | 1 |
| Iurasov, VV | 1 |
| Nikushkin, EV | 1 |
| Zhigal'tsev, IV | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Fillebeen, C | 1 |
| Mitchell, V | 1 |
| Dexter, D | 1 |
| Benaissa, M | 1 |
| Beauvillain, J | 1 |
| Spik, G | 1 |
| Pierce, A | 1 |
| Ferger, B | 1 |
| Teismann, P | 1 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Oertel, WH | 1 |
| Klivenyi, P | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Jiang, D | 1 |
| Ueda, S | 1 |
| Aikawa, M | 1 |
| Ishizuya-Oka, A | 1 |
| Yamaoka, S | 1 |
| Koibuchi, N | 1 |
| Yoshimoto, K | 1 |
| Ben, V | 1 |
| Blin, O | 1 |
| Bruguerolle, B | 1 |
| Disshon, KA | 1 |
| Dluzen, DE | 1 |
| Bezard, E | 2 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Bloch, B | 1 |
| Gross, CE | 2 |
| Nash, JE | 1 |
| Brotchie, JM | 2 |
| Richfield, EK | 1 |
| Baggs, RB | 1 |
| Tank, AW | 1 |
| Costa, G | 1 |
| Abin-Carriquiry, JA | 1 |
| Dajas, F | 1 |
| Philhower, J | 1 |
| Miller, GW | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Belforte, JE | 1 |
| Magariños-Azcone, C | 1 |
| Armando, I | 1 |
| Buño, W | 1 |
| Pazo, JH | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Kitazawa, M | 1 |
| Anantharam, V | 1 |
| Kanthasamy, AG | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Leret, ML | 1 |
| San Millán, JA | 1 |
| Fabre, E | 1 |
| Gredilla, R | 1 |
| Barja, G | 1 |
| Fredduzzi, S | 1 |
| Moratalla, R | 1 |
| Monopoli, A | 1 |
| Cuellar, B | 1 |
| Xu, K | 1 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Schwarzschild, MA | 1 |
| Chen, JF | 1 |
| Hoehn, MM | 1 |
| Crowley, TJ | 1 |
| Rutledge, CO | 1 |
| Pope, A | 1 |
| Simpson, K | 1 |
| Taggart, J | 1 |
| Smith, MG | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 1 |
| Hsiao, J | 1 |
| Bankiewicz, KS | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Weiser, M | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Fazzini, E | 1 |
| Durso, R | 1 |
| Davoudi, H | 1 |
| Szabo, GK | 1 |
| Albert, ML | 1 |
| Rouillard, C | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Jenner, PG | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Bédard, P | 1 |
| Daigle, M | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Wiener, HL | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Sershen, H | 1 |
| Ueki, A | 1 |
| Chong, PN | 1 |
| Chivers, JK | 1 |
| Jackson, EA | 1 |
| Gibb, WR | 1 |
| Hadjiconstantinou, M | 1 |
| Mariani, AP | 1 |
| Neff, NH | 1 |
| Russ, H | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 1 |
| Collins, MA | 2 |
| Neafsey, EJ | 2 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Kenny, AM | 1 |
| Schneider, MB | 1 |
| Baden, DR | 1 |
| Pfeiffer, RF | 1 |
| Murrin, LC | 1 |
| Perry, TL | 2 |
| Jones, K | 2 |
| Hansen, S | 2 |
| Wall, RA | 1 |
| Saitoh, T | 1 |
| Hood, TW | 1 |
| Domino, EF | 1 |
| Greenberg, HS | 1 |
| Ghilardi, MF | 1 |
| Chung, E | 1 |
| Bodis-Wollner, I | 1 |
| Dvorzniak, M | 1 |
| Glover, A | 1 |
| Onofrj, M | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Schultz, W | 1 |
| Scarnati, E | 1 |
| Sundström, E | 1 |
| Tsutsumi, T | 1 |
| Jonsson, G | 1 |
| Zimmerman, DM | 1 |
| Cantrell, BE | 1 |
| Reel, JK | 1 |
| Hemrick-Luecke, SK | 1 |
| Fuller, RW | 1 |
| Eidelberg, E | 1 |
| Brooks, BA | 1 |
| Morgan, WW | 1 |
| Walden, JG | 1 |
| Kokemoor, RH | 1 |
| Cheng, BY | 1 |
| Hurley-Gius, K | 1 |
| Ung-Chhun, NA | 1 |
| Pronger, DA | 1 |
| Christensen, MA | 1 |
| Hurley-Gius, D | 1 |
| Heikkila, RE | 1 |
| Sonsalla, PK | 1 |
112 other studies available for 3,4-dihydroxyphenylacetic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Behavior, Animal; Discrimination Learning; Dopam | 2021 |
Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Autonomic Nervous System Diseases; Baroref | 2021 |
Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 2017 |
Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Flavonoids; Gene Expression Regulatio | 2018 |
Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cognition; Dopamine; Female; Flavonoids; Homovanilli | 2019 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
[Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acrylamides; Animals; | 2013 |
Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Dopamine; Electron | 2015 |
Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Combretum; Dopamine; Gene Expression Regulation; Homovanill | 2016 |
Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Blotting, Western; Chrom | 2009 |
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Catalase; Cy | 2013 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2002 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Casts, Surgical; Corpus Stri | 2003 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Syner | 2002 |
Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line, Transformed; Corpus Striatum; | 2003 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; | 2005 |
Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Embryo, Ma | 2006 |
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Biotransformation; Catecholamines; Foreli | 2006 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antip | 2007 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1984 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; A | 1993 |
Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopami | 1994 |
Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressiv | 1994 |
Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Exc | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervatio | 1994 |
MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Drug Resis | 1993 |
Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 1994 |
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopam | 1993 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Dopamine; Injections; Iron; | 1995 |
Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Drug Administration Schedule; Dr | 1996 |
Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Dopamine Agents; Enzyme Inhibitors; Homov | 1996 |
Dynamic regulation of striatal dopaminergic grafts during locomotor activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Transplantation; Corpus Striatum; Dopamine; Extracellu | 1996 |
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Basal Ganglia; Biomarkers; Cerebral Cortex; | 1996 |
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Aromat | 1997 |
Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bone Morphogenetic Proteins; Corpus Striatum; Dopamine; Gro | 1997 |
[Effect of acupuncture and Chinese medicine treatment on brain dopamine level of MPTP-lesioned C57BL mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acupuncture Therapy; A | 1996 |
Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Carbolines; Cells, Cultured; Do | 1998 |
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Cycloheximide; Disease Model | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Prot | 1998 |
Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Mo | 1998 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Topics: 1-Naphthylamine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Antidepressive Agents, Second-Genera | 1998 |
Repin-induced neurotoxicity in rodents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytotoxins; Dopamine; Encephalomalacia; Glutathione; Immuno | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agen | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
[Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Intran | 1999 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalase; Cor | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antibodies; Disease Models, Animal; Dopamine; Free R | 2000 |
Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 1999 |
Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Est | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Cyclic AMP; Disease | 2000 |
The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Weight; Carrier Proteins; Cell Count; Corpus Striatum; | 2000 |
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; D | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L- | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Cell Survival; Chromatography, High Pressure Liq | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2002 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Anima | 2002 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1992 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cats; Caudate Nucleus; Dopamine; Female; | 1992 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homov | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichina | 1989 |
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 1989 |
Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allylamine; Animals; B | 1989 |
GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1989 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D | 1986 |
2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Mice; | 1988 |
Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Clomipramine; | 1988 |
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic | 1988 |
Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatograph | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1986 |
Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1986 |
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1986 |
Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1987 |
Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
The use of the MPTP-treated mouse as an animal model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |